Structure Therapeutics
Qinxuan (Steven) Wang has a diverse work experience in the fields of pharmaceuticals and research. Qinxuan(Steven) started their career as a Public Relations Intern at Thermo Fisher Scientific in 2015. Qinxuan(Steven) then worked as a Teaching Assistant at the University of Houston from 2016 to 2019, followed by a role as a Research Assistant from 2019 to 2021. During this time, they also interned as a MedChem Scientist at Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
In 2021, Qinxuan joined The Janssen Pharmaceutical Companies of Johnson & Johnson as a MedChem Scientist. Qinxuan(Steven) held this position until 2023, when they joined Structure Therapeutics as a Senior Scientist. Qinxuan(Steven)'scurrent role at Structure Therapeutics is ongoing.
Overall, Qinxuan (Steven) Wang has demonstrated a strong commitment to the pharmaceutical industry, gaining valuable experience in both research and development.
Qinxuan (Steven) Wang began their education in 2012 at Fudan University, where they pursued a Bachelor's degree in Chemistry. In 2013, they also took on a second major in Economics at the same university, which they completed in 2016. During their time at Fudan University, they participated in a short-term research program in Organometallic Chemistry at the University of Münster in 2015. After completing their undergraduate studies, Wang continued their education at the University of Houston from 2016 to 2021, where they obtained a Doctor's degree in Organic Chemistry.
This person is not in any offices
Structure Therapeutics
Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations inbiologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team’s deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity.